天福(06868.HK)與薩摩亞公司訂立經重續薩摩亞總加工協議
格隆匯12月3日丨天福(06868.HK)發佈公告,2019年12月3日,公司與天福(薩摩亞)控股有限公司公司訂立經重續薩摩亞總加工協議,據此,薩摩亞集團同意提供加工服務以提升混合及陳茶茶葉的質量,自2020年1月1日起至2022年12月31日止為期三年,截至2022年12月31日止三個年度經重續年度上限分別將不超過人民幣500萬元、人民幣500萬元及人民幣500萬元。
由於薩摩亞公司由李家麟(公司主要股東兼董事)全資擁有,因此,薩摩亞公司為公司一名核心關連人士的聯繫人,而訂立經重續薩摩亞總加工協議及其項下擬進行的交易根據上市規則第十四A章構成公司的持續關連交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.